Compare EVF & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVF | XTNT |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 82.6M |
| IPO Year | N/A | N/A |
| Metric | EVF | XTNT |
|---|---|---|
| Price | $5.31 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 93.3K | ★ 201.0K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | ★ 10.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.94 | 0.01 |
| Revenue | N/A | ★ $133,083,000.00 |
| Revenue This Year | N/A | $15.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.74 | $59.48 |
| Revenue Growth | N/A | ★ 16.88 |
| 52 Week Low | $5.20 | $0.34 |
| 52 Week High | $6.84 | $0.95 |
| Indicator | EVF | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 41.30 |
| Support Level | $5.25 | $0.68 |
| Resistance Level | $5.38 | $0.74 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 36.60 | 14.71 |
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.